수의용 생물제제 시장 예측(2026-2032년)

The Veterinary Biological Product Market is projected to grow by USD 4.13 billion at a CAGR of 4.90% by 2032.

Veterinary Biological Products: Executive Overview

Veterinary biological products include vaccines, antisera, immunological reagents, and related biological preparations used to prevent, diagnose, or control animal diseases. Their importance is increasing as animal health programs address livestock productivity, companion-animal care, zoonotic disease risks, food safety, and international movement of animals and animal products. Demand conditions differ by species, disease burden, veterinary infrastructure, regulatory requirements, and the adoption of preventive healthcare practices.

Prevention, Regulation, and One Health Reshape the Landscape

The sector is shifting from reactive treatment toward prevention, surveillance, and coordinated disease control. Stronger attention to antimicrobial stewardship, biosecurity, traceability, animal welfare, and zoonotic disease preparedness is increasing the role of biological products in national and farm-level health programs. Regulatory expectations are also emphasizing product quality, safety, efficacy, cold-chain integrity, pharmacovigilance, and evidence-based use. These changes favor solutions that can be integrated into vaccination schedules, herd-health protocols, diagnostic workflows, and public-health systems.

Artificial Intelligence Improves Discovery, Diagnostics, and Deployment

Artificial intelligence can support veterinary biological product development by identifying antigen candidates, analyzing pathogen sequences, modeling immune responses, and prioritizing laboratory experiments. In deployment, machine-learning tools can help interpret diagnostic data, detect disease patterns, optimize vaccination timing, and identify gaps in herd or population coverage. The value of these applications depends on representative data, validated models, interoperable records, cybersecurity, and veterinary oversight. AI should therefore complement-not replace-clinical judgment, laboratory confirmation, regulatory review, and responsible stewardship.

Regional Insights: Uneven Infrastructure Creates Distinct Priorities

North America combines advanced veterinary infrastructure, established regulatory systems, and demand across livestock, aquaculture, and companion animals, while disease surveillance and antimicrobial stewardship remain central priorities. Latin America places strong emphasis on livestock health, export compliance, biosecurity, and access across diverse production systems. Europe prioritizes animal welfare, traceability, scientific substantiation, and harmonized regulatory processes. The Middle East requires solutions suited to imported animals, transboundary disease risks, water and climate constraints, and expanding food-security programs. Africa faces varied access to veterinary services, cold-chain limitations, and significant needs in livestock disease control and surveillance. Asia-Pacific spans highly advanced markets and rapidly developing production systems, creating demand for scalable prevention, local manufacturing capacity, and responses to dense animal populations and emerging pathogens.

Group Insights: Trade, Security, and Regulatory Coordination

ASEAN's diverse production systems and cross-border animal movement make regional surveillance, harmonized standards, and practical cold-chain networks important. BRICS members have substantial livestock, aquaculture, and companion-animal needs, with priorities shaped by domestic manufacturing, food security, disease control, and regulatory coordination. The European Union emphasizes common standards, traceability, animal welfare, and coordinated disease-management frameworks. G7 members generally have mature regulatory and veterinary systems, with focus on innovation, resilience, antimicrobial stewardship, and One Health preparedness. GCC countries place emphasis on food security, imported livestock, biosecurity, and reliable supply channels. NATO members have varied animal-health profiles but share interests in resilience, emergency preparedness, supply continuity, and protection against transboundary biological threats.

Country Insights: Diverse Disease-Control and Access Priorities

Australia emphasizes livestock biosecurity, export assurance, wildlife interfaces, and geographically dispersed veterinary delivery. Brazil focuses on cattle, poultry, swine, aquaculture, regional disease control, and international market access. Canada combines livestock and companion-animal needs with surveillance, cold-climate logistics, and strong regulatory oversight. China is addressing large-scale production, disease prevention, domestic capability, and modernization of veterinary services. France, Germany, Italy, and Spain operate within the European regulatory framework while responding to livestock, companion-animal, welfare, and biosecurity priorities. India faces extensive livestock diversity, uneven veterinary access, and major needs in preventive coverage and rural delivery. Japan emphasizes advanced quality standards, aging demographics, companion-animal care, and preparedness for animal disease events. Mexico balances livestock production, cross-border trade, and access across varied regions. Russia's priorities include domestic production capacity, animal disease control, and geographically broad distribution. South Korea combines intensive production, strict biosecurity, and technologically enabled veterinary care. The United Kingdom focuses on biosecurity, surveillance, regulatory assurance, and animal welfare. The United States has broad demand across livestock, poultry, aquaculture, and companion animals, supported by sophisticated regulation, diagnostics, and disease-management programs.

Actions for Leaders: Build Resilient, Evidence-Based Prevention Systems

Industry leaders should align product development with clearly defined disease-control outcomes, species-specific use cases, and regulatory evidence requirements. Strengthening formulation stability, cold-chain performance, local technical support, and training can improve adoption where delivery infrastructure is uneven. Partnerships with veterinary authorities, laboratories, producers, universities, and public-health organizations can improve surveillance and response coordination. Leaders should also establish transparent stewardship policies, post-market monitoring, responsible data governance, and AI validation protocols. Portfolio resilience requires attention to critical inputs, manufacturing continuity, regional registration pathways, and contingency plans for outbreaks and logistics disruptions.

Research Methodology: Structured Review of Verified Market Evidence

This executive summary is based on the defined veterinary biological product category and the required regional, group, and country coverage. The analysis uses a structured framework linking product applications with disease prevention, veterinary infrastructure, regulation, trade, biosecurity, One Health priorities, and technology adoption. Geographic observations are presented qualitatively and are limited to established market drivers and operating conditions. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included. Interpretations should be validated against current legislation, official disease surveillance, veterinary authorities, and product registration records before strategic decisions are made.

Conclusion: Prevention and System Integration Define Future Competitiveness

Veterinary biological products are becoming more central to resilient animal-health systems because they connect disease prevention, food security, animal welfare, zoonotic-risk management, and responsible antimicrobial use. Regional and country conditions remain highly varied, making adaptable products, reliable delivery systems, strong evidence, and regulatory alignment essential. Organizations that combine scientific rigor with surveillance, digital capability, local partnerships, and supply-chain resilience will be better positioned to support effective, sustainable animal-health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Biological Product Market, by Product Type

• 7.1. Introduction
• 7.2. Antitoxins
• 7.3. Diagnostics
• 7.4. Vaccines

8. Veterinary Biological Product Market, by Animal Type

• 8.1. Introduction
• 8.2. Aquaculture
• 8.3. Companion Animals
  • 8.3.1. Canine
  • 8.3.2. Equine
  • 8.3.3. Feline
• 8.4. Livestock
  • 8.4.1. Bovine
  • 8.4.2. Caprine
  • 8.4.3. Ovine
  • 8.4.4. Porcine
• 8.5. Poultry

9. Veterinary Biological Product Market, by Disease Indication

• 9.1. Introduction
• 9.2. Bacterial Diseases
  • 9.2.1. Anthrax
  • 9.2.2. Brucellosis
  • 9.2.3. Salmonellosis
• 9.3. Parasitic Diseases
• 9.4. Viral Diseases
  • 9.4.1. Foot And Mouth Disease
  • 9.4.2. Newcastle Disease
  • 9.4.3. Rabies

10. Veterinary Biological Product Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Farmers
• 10.4. Government Agencies
• 10.5. Veterinary Hospitals

11. Veterinary Biological Product Market, by Route Of Administration

• 11.1. Introduction
• 11.2. Injection
  • 11.2.1. Intramuscular
  • 11.2.2. Intravenous
  • 11.2.3. Subcutaneous
• 11.3. Nasal
• 11.4. Oral

12. Veterinary Biological Product Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Veterinary Biological Product Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Veterinary Biological Product Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Animalcare Ltd
• 16.2. Bimeda Inc
• 16.3. Biogenesis Bago SA
• 16.4. Boehringer Ingelheim International GmbH
• 16.5. Ceva Sante Animale
• 16.6. Chongqing Zhifei Biological Products Co Ltd
• 16.7. Dechra Pharmaceuticals plc
• 16.8. Eco Animal Health Group Limited
• 16.9. Elanco Animal Health Incorporated
• 16.10. Hester Biosciences Ltd
• 16.11. HIPRA SA
• 16.12. Indian Immunologicals Ltd
• 16.13. Kyoritsu Seiyaku Corporation
• 16.14. Merck & Co Inc
• 16.15. Neogen Corporation
• 16.16. Norbrook Laboratories Ltd
• 16.17. Phibro Animal Health Corporation
• 16.18. Shenzhen Kangtai Biological Products Co Ltd
• 16.19. Tianjin Ringpu Bio-Technology Co Ltd
• 16.20. Utrecht Biologicals BV
• 16.21. Vetanco SA
• 16.22. Vetoquinol SA
• 16.23. Virbac SA
• 16.24. Zoetis Inc

17. Key Experts